Pharming Group Nv Stock Fundamentals
| PHGUF Stock | USD 0.75 0.07 8.54% |
Pharming Group NV fundamentals help investors to digest information that contributes to Pharming Group's financial success or failures. It also enables traders to predict the movement of Pharming Pink Sheet. The fundamental analysis module provides a way to measure Pharming Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharming Group pink sheet.
Pharming |
Pharming Group NV Company Return On Equity Analysis
Pharming Group's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Pharming Group Return On Equity | 0.17 |
Most of Pharming Group's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharming Group NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Pharming Group NV has a Return On Equity of 0.1669. This is 100.7% lower than that of the Healthcare sector and 100.46% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 153.84% lower than that of the firm.
Pharming Group NV Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pharming Group's current stock value. Our valuation model uses many indicators to compare Pharming Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharming Group competition to find correlations between indicators driving Pharming Group's intrinsic value. More Info.Pharming Group NV is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.39 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Pharming Group NV is roughly 2.60 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharming Group's earnings, one of the primary drivers of an investment's value.Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
| All Next | Launch Module |
Pharming Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0643 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 721.19 M | |||
| Shares Outstanding | 652.41 M | |||
| Shares Owned By Insiders | 1.97 % | |||
| Shares Owned By Institutions | 16.43 % | |||
| Price To Earning | 18.97 X | |||
| Price To Book | 3.94 X | |||
| Price To Sales | 3.69 X | |||
| Revenue | 167.68 M | |||
| Gross Profit | 177.73 M | |||
| EBITDA | 41.22 M | |||
| Net Income | 16 M | |||
| Cash And Equivalents | 189.96 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 122.65 M | |||
| Debt To Equity | 0.75 % | |||
| Current Ratio | 5.22 X | |||
| Book Value Per Share | 0.30 X | |||
| Cash Flow From Operations | 37.84 M | |||
| Earnings Per Share | 0.05 X | |||
| Target Price | 24.89 | |||
| Number Of Employees | 277 | |||
| Beta | 0.98 | |||
| Market Capitalization | 880.76 M | |||
| Total Asset | 350.55 M | |||
| Retained Earnings | (273 M) | |||
| Working Capital | 23 M | |||
| Current Asset | 41 M | |||
| Current Liabilities | 18 M | |||
| Z Score | 4.2 | |||
| Net Asset | 350.55 M |
About Pharming Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharming Group NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Pharming Grp operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 277 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Pharming Pink Sheet
When determining whether Pharming Group NV is a strong investment it is important to analyze Pharming Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pharming Group's future performance. For an informed investment choice regarding Pharming Pink Sheet, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.